CERS
Cerus CorporationNASDAQHealthcare$1.86-0.53%ClosedMarket Cap: $357.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.49
P/S
1.72
EV/EBITDA
-57.18
DCF Value
$2.19
FCF Yield
0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.5%
Operating Margin
-4.2%
Net Margin
-7.6%
ROE
-26.4%
ROA
-7.0%
ROIC
-5.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $57.8M | 51.5% | $-641.0K | $-2.2M | $-0.01 | — |
| FY 2025 | $206.1M | 54.5% | $-8.7M | $-15.6M | $-0.08 | — |
| Q3 2025 | $52.7M | 53.4% | $1.2M | $-19.0K | $-0.00 | — |
| Q2 2025 | $52.4M | 55.2% | $-3.4M | $-5.7M | $-0.03 | — |
| Q1 2025 | $43.2M | 58.8% | $-5.9M | $-7.7M | $-0.04 | — |
| Q4 2024 | $50.8M | 53.9% | $-1.4M | $-2.5M | $-0.01 | — |
| FY 2024 | $180.3M | 55.2% | $-14.2M | $-20.9M | $-0.11 | — |
| Q3 2024 | $46.0M | 56.9% | $-961.0K | $-2.9M | $-0.02 | — |
| Q2 2024 | $45.1M | 54.7% | $-3.8M | $-5.8M | $-0.03 | — |
| Q1 2024 | $38.4M | 55.4% | $-8.0M | $-9.7M | $-0.05 | — |
| Q4 2023 | $46.8M | 55.5% | $976.0K | $-1.3M | $-0.01 | — |
| FY 2023 | $156.4M | 55.3% | $-30.1M | $-37.5M | $-0.21 | — |